EB8F7B74-694A-4F9F-9C0B-F04006033CA4
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 11.727989487516425
- age_years
- 54
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.632
- INTERFERON_ALPHA_RESPONSE+0.630
- E2F_TARGETS+0.606
- DNA_REPAIR+0.598
- INTERFERON_GAMMA_RESPONSE+0.576
- MYC_TARGETS_V2+0.563
- G2M_CHECKPOINT+0.560
- UNFOLDED_PROTEIN_RESPONSE+0.499
- MTORC1_SIGNALING+0.488
- TNFA_SIGNALING_VIA_NFKB+0.485
Top 10 suppressed
- KRAS_SIGNALING_DN-0.411
- SPERMATOGENESIS-0.269
- MYOGENESIS-0.257
- BILE_ACID_METABOLISM-0.195
- APICAL_SURFACE-0.141
- PANCREAS_BETA_CELLS-0.102
- ESTROGEN_RESPONSE_EARLY-0.053
- XENOBIOTIC_METABOLISM+0.003
- HEME_METABOLISM+0.006
- ESTROGEN_RESPONSE_LATE+0.083
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 1B326CC6-3916-4D1D-A238-7B3C42F3E6C6 | — | — | 0.975 |
| 2 | 6B8CAF74-45C6-4C20-8126-A99F73346198 | — | — | 0.971 |
| 3 | 55E3F1FB-D55D-42F8-A9E1-7828F7BFF595 | — | — | 0.971 |
| 4 | 93A7AA5D-FA07-470A-9FD3-306EA577D3C4 | — | — | 0.970 |
| 5 | 0E66EFB0-712B-4A52-8F75-A37F030CABEF | — | — | 0.967 |
| 6 | D494D692-9EC2-429A-A0FE-696D2A152D4A | — | — | 0.966 |
| 7 | 94640BD8-E1D9-482D-A597-4790F6EEA6B7 | — | — | 0.964 |
| 8 | 9BB12A25-E833-4055-8CEF-814EA5454F11 | — | — | 0.960 |
| 9 | 7876A884-F031-42AB-ADC0-89589760FB6B | — | — | 0.959 |
| 10 | DC01D165-E257-49D6-8B9B-37CA7DE398F6 | — | — | 0.959 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 43 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.632 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.630 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.606 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.598 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.576 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.563 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.560 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.499 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.488 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.485 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.439 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.426 | Inavolisib | — uncovered |
| APOPTOSIS | 0.415 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.410 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.402 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.393 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.380 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.378 | Remibrutinib | — uncovered |
| HYPOXIA | 0.369 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.350 | Inavolisib | — uncovered |